Development of a rotavirus vaccine: clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine, RotaTeq (Q37652537)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article published on December 2009

Language	Label	Description	Also known as
English	Development of a rotavirus vaccine: clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine, RotaTeq	scientific article published on December 2009

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

1 reference

Europe PubMed Central

Development of a rotavirus vaccine: clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine, RotaTeq (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

1 reference

based on heuristic

inferred from title

rotavirus vaccine

1 reference

based on heuristic

inferred from title

1

object named as

Max Ciarlet

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

author name string

Florian Schödel

2

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

language of work or name

0 references

publication date

1 December 2009

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

27 Suppl 6

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

G72-81

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Rotavirus and severe childhood diarrhea

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Global Illness and Deaths Caused by Rotavirus Disease in Children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Cost-effectiveness and potential impact of rotavirus vaccination in the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

The impact of rotavirus gastroenteritis on the family

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Recommendations for the classification of group A rotaviruses using all 11 genomic RNA segments

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Characterization of novel VP7, VP4, and VP6 genotypes of a previously untypeable group A rotavirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Evidence of interspecies transmission and reassortment among avian group A rotaviruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Molecular analysis of the VP7 gene of pheasant rotaviruses identifies a new genotype, designated G23.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Immunogenicity and safety of live oral attenuated bovine rotavirus vaccine strain RIT 4237 in adults and young children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Protection of infants against rotavirus diarrhoea by RIT 4237 attenuated bovine rotavirus strain vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

A comparative trial of rhesus monkey (RRV-1) and bovine (RIT 4237) oral rotavirus vaccines in young children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Failure of live, attenuated oral rotavirus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Protection of Peruvian children against rotavirus diarrhea of specific serotypes by one, two, or three doses of the RIT 4237 attenuated bovine rotavirus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

A field study of the safety and efficacy of two candidate rotavirus vaccines in a Native American population

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Sequence analysis of the VP4, VP6, VP7, and NSP4 gene products of the bovine rotavirus WC3.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Protective effect of WC3 vaccine against rotavirus diarrhea in infants during a predominantly serotype 1 rotavirus season

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Evaluation of WC3 rotavirus vaccine and correlates of protection in healthy infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Evaluation of the efficacy of a low-passage bovine rotavirus (strain WC3) vaccine in children in Central Africa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Evaluation of rhesus rotavirus vaccine (MMU 18006) in infants and young children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Prolonged efficacy of rhesus rotavirus vaccine in Swedish children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Protection against severe rotavirus diarrhoea by rhesus rotavirus vaccine in Venezuelan infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Efficacy and safety of high-dose rhesus-human reassortant rotavirus vaccine in Native American populations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Serotype 1 reassortant of bovine rotavirus WC3, strain WI79-9, induces a polytypic antibody response in infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Immune protection of infants against rotavirus gastroenteritis by a serotype 1 reassortant of bovine rotavirus WC3.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Evaluation of the protective efficacy of a serotype 1 bovine-human rotavirus reassortant vaccine in infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus Gastroenteritis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Effectiveness of Lanzhou lamb rotavirus vaccine against rotavirus gastroenteritis requiring hospitalization: a matched case-control study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Genomic characterization of a novel group A lamb rotavirus isolated in Zaragoza, Spain

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Safety, efficacy, and immunogenicity of 2 doses of bovine-human (UK) and rhesus-rhesus-human rotavirus reassortant tetravalent vaccines in Finnish children.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Early phase II trial of human rotavirus vaccine candidate RV3

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

A dose-escalation safety and immunogenicity study of live attenuated oral rotavirus vaccine 116E in infants: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Intranasal or oral immunization of inbred and outbred mice with murine or human rotavirus VP6 proteins protects against viral shedding after challenge with murine rotaviruses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Intranasal administration of 2/6-rotavirus-like particles with mutant Escherichia coli heat-labile toxin (LT-R192G) induces antibody-secreting cell responses but not protective immunity in gnotobiotic pigs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequency.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Rotavirus infection in infants as protection against subsequent infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral poliovirus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Experience of pentavalent human-bovine reassortant rotavirus vaccine among healthy infants in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenic

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Decline in cases of rotavirus gastroenteritis presenting to The Children's Hospital of Philadelphia after introduction of a pentavalent rotavirus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

Cost-effectiveness analysis of a rotavirus immunization program for the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical studies of a quadrivalent rotavirus vaccine in Venezuelan infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

based on heuristic

inferred from DOI database lookup

Subunit rotavirus vaccine administered parenterally to rabbits induces active protective immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.107

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2009.09.107

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

release_tonbmm4uefatha3guqwhxkwaie

1 reference

https://api.fatcat.wiki/v0/release/tonbmm4uefatha3guqwhxkwaie

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37652537&oldid=1844397851"